Population Pharmacokinetics of Ipilimumab in Combination With Nivolumab in Patients With Advanced Solid Tumors

Ipilimumab is a fully human monoclonal antibody approved for the treatment of melanoma as monotherapy and for the treatment of melanoma, renal cell carcinoma, and colorectal cancer in combination with nivolumab. Ipilimumab time‐varying clearance (CL) was assessed by a population pharmacokinetics (PP...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanghavi, Kinjal, Zhang, Jason, Zhao, Xiaochen, Feng, Yan, Statkevich, Paul, Sheng, Jennifer, Roy, Amit, Vezina, Heather E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966186/
https://www.ncbi.nlm.nih.gov/pubmed/31709718
http://dx.doi.org/10.1002/psp4.12477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966186/
https://www.ncbi.nlm.nih.gov/pubmed/31709718
http://dx.doi.org/10.1002/psp4.12477

Ejemplares similares